Difference between revisions of "Giulino-Roth L, et al. Mol. cancer therapeutics (2017) cited as Ref 364 in DOI: 10.1038/s41392-020-0110-5 (Q9627)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 16, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma (English) | ||
| Property / title: Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:00, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Giulino-Roth L, et al. Mol. cancer therapeutics (2017) cited as Ref 364 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Giulino-Roth L
0 references
2017
0 references
Mol. cancer therapeutics
0 references
16
0 references
Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma (English)
0 references
